Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 41 Issue 3, March 2020

Acetyl-CoA carboxylases (ACC1/ACC2) are important drug targets for NASH treatment. Gao et al developed WZ66, a novel inhibitor of ACCs that enables the decrease of de novo lipogenesis, the inactivation of Kupffer cells and hepatic stellate cells. WZ66 also altered the plasma lipids profile and gut microbiota composition.

Article

Search

Quick links